GEM
SYRE icon

Global Endowment Management’s Spyre Therapeutics SYRE Stock Holding History

Global Endowment Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$917K Hold
18,184
– – 0.1% 56
2025
Q4 		$596K Hold
18,184
– – 0.07% 72
2025
Q3 		$305K Hold
18,184
– – 0.04% 119
2025
Q2 		$272K Hold
18,184
– – 0.04% 114
2025
Q1 		$293K Hold
18,184
– – 0.04% 111
2024
Q4 		$423K Hold
18,184
– – 0.05% 117
2024
Q3 		$535K Hold
18,184
– – 0.05% 107
2024
Q2 		$428K Hold
18,184
– – 0.05% 115
2024
Q1 		$690K Sell
18,184
-495,252
-96% -$14.3M 0.07% 93
2023
Q4 		$11M Buy
+513,436
New +$7.07M 1.23% 14

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Global Endowment Management's SYRE Position: Q1 2026 in Review

Global Endowment Management held its Spyre Therapeutics (SYRE) position steady in Q1 2026 at 18,184 shares worth $917K. The position accounts for 0.1% of the portfolio, ranked #56.

Global Endowment Management first reported a position in SYRE in Q4 2023 and has held it in 10 quarters since. The position peaked at $11M in Q4 2023. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Global Endowment Management held 18,184 shares of Spyre Therapeutics worth $917K as of Q1 2026.
  • Global Endowment Management left its Spyre Therapeutics share count unchanged in Q1 2026.
  • Spyre Therapeutics made up 0.1% of Global Endowment Management's portfolio in Q1 2026, its #56 holding.
  • Global Endowment Management first reported a position in Spyre Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Global Endowment Management's Spyre Therapeutics position peaked at $11M in Q4 2023.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Global Endowment Management's 13F filing for Q1 2026, filed 14 May 2026.